[CAS NO. 104987-12-4] Ascomycin
PRODUCTS SPECIFICATIONS [104987-12-4]
DESCRIPTION [104987-12-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 792.01 |
| Molecular Formula | C43H69NO12 |
| SMILES | O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@H](O)CC4)[C@H](C)[C@@H](O)CC3=O |
4 Publications Citing Use of MCE
Summary
Ascomycin (Immunomycin; FR-900520; FK520) is an ethyl analog of Tacrolimus (FK506) with strong immunosuppressant properties. Ascomycin is also a macrocyclic polyketide antibiotic with multiple biological activities such as anti-malarial, anti-fungal and anti-spasmodic. Ascomycin prevents graft rejection and has potential for varying skin ailments research [1] [2] .
IC50 & Target
|
Plasmodium |
In Vitro
Ascomycin (FR-900520) suppresses immune response in vitro with an IC
50
value of 0.55 nM for mouse mixed lymphocyte reaction
[1]
.
Ascomycin is a powerful calcium-dependent serine/threonine protein phosphatase (calcineurin [CaN], protein phosphatase 2B) inhibitors. Its mechanism of action involves the formation of a molecular complex with the intracellular FK506-binding protein-12 (FKBP12), thereby acquiring the ability to interact with CaN and to interfere with the dephosphorylation of various substrates
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Ascomycin (FR-900520; i.m.; 0.32-32 mg/kg; 5 days a week; for 2 weeks) clearly prolongs skin allograft survival in rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | WKA rats (8-10 weeks old) transplanted with F344 skin allografts [1] |
| Dosage: | 0.32 mg/kg, 1 mg/kg, 3.2 mg/kg, 10 mg/kg, 32 mg/kg |
| Administration: | i.m.; 5 days a week; for 2 weeks |
| Result: | Clearly prolonged skin allograft survival in rats |
Appearance
Solid
Source
Streptomyces tubercidicus
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 39 mg/mL ( 49.24 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.2626 mL | 6.3131 mL | 12.6261 mL |
| 5 mM | 0.2525 mL | 1.2626 mL | 2.5252 mL |
| 10 mM | 0.1263 mL | 0.6313 mL | 1.2626 mL |
References
- [1] Hatanaka H, et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1988 Nov;41(11):1592-601.
- [2] Krishika Sambyal, et al. Bioprocess and genetic engineering aspects of ascomycin production: a review. J Genet Eng Biotechnol. 2020 Nov 19;18(1):73.
- [3] Germán Sierra-Paredes, et al. Ascomycin and FK506: pharmacology and therapeutic potential as anticonvulsants and neuroprotectants. CNS Neurosci Ther. Spring 2008;14(1):36-46.
Synonyms